在早期研究中，巨大的不可溶的Aβ斑块被认为是引发患者症状的头号元凶。科学家们普遍认为，这些斑块的形成是AD的核心病理特征，也是导致认知功能障碍的主要原因。因此，大量的研究资源和精力被投入到针对Aβ斑块的治疗策略中，希望能够通过清除这些斑块来改善患者的 ...

经过十余年迭代优化，科学家最终将靶点锁定在Aβ聚集级联反应中最具毒性的可溶性寡聚体阶段。新一代抗体药物终于突破瓶颈——2023年完全获批的 ...

Aβ的“前身”是正常存在于神经元中的淀粉样前体蛋白（APP），在某些情况下被蛋白酶错误切割而产生。在AD患者的大脑中，Aβ的生成源源不断地 ...

Notably, microglia spatially associated with amyloid plaques exhibited increased expression of TREM2 and ApoE compared to ...

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer ...

CHENGDU, China, March 26, 2025 /PRNewswire/ -- March. 25, 2025, Keymed Biosciences Inc. (HKEX: 02162) announced its annual results of 2024, along with a corporate update.

A live webcast of the fireside chat may be accessed by visiting the Events page of the Company’s website at www.promisneurosciences.com, and will be available for at least 30 days following the event.